Generex Receives New US Patent for its Proprietary Buccal Drug Delivery Platform Technologies
Patent covers Method for Administration of Insulin to the Buccal Region
This new patent increases the number of patents related to the Company’s proprietary buccal drug delivery platform technologies to 158 issued patents, 22 of which are United States patents. Generex has a total of 105 patent applications pending in various jurisdictions around the world.
“We continue to bolster the Company’s intellectual property protection with each new patent issuance”, stated Rose C. Perri, the Company’s Chief Operating Officer. “The issuance of patents in key markets like the United States strengthens the Company’s intellectual property assets and is timely as our flagship product, Generex Oral-lyn™, is available under the FDA’s expanded access Treatment IND program.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.